Amgen (AMGN) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Amgen Inc (AMGN) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, Amgen is a large, cash-generating biotech company that sells established biologic drugs and biosimilars, with the market treating it more like a steady healthcare compounder than a high-risk moonshot biotech. > **📍 Basic Profile** > > Market Cap **$187.5 billion** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$347.8** > **⚡ 3 Things You Should Know** > > 1. 💰 Cash Machine, Not a Story Stock: Amgen’s gross margin is a huge **73.3%** and net margin is **21.0%**, which tells you this business still throws off serious profits. In other words, this is not a “hope and hype” biotech—it already earns real money at scale. > > 2. ⚠️ Balance Sheet Looks More Levered Than It First Appears: Debt-to-equity is extremely high at **6.31x**, and the current ratio is only **1.14**. Interest coverage is still solid at **13.3x**, so it’s not an emergency, but it does mean Amgen has less balance-sheet flexibility than its stable business model might suggest. > > 3. 📈 The Stock Is Priced for Consistency, Not Explosive Upside: At about **24.4x earnings** and sitting around **67% up its 52-week range**, the market is paying a respectable premium for durability, dividend income, and execution. Basically, investors are betting Amgen keeps delivering dependable earnings beats rather than suddenly becoming a hyper-growth biotech. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Strong💪 | Net margin 20.98%, very strong for large-cap biotech | > | Growth Rate | Steady📈 | 3-year revenue CAGR 11.77%, EPS CAGR 5.51% | > | Financial Health | Moderate💛 | Debt-to-equity 6.31x, but interest coverage 13.26x | > | Valuation | Fair | PE 24.39x | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Amgen develops and sells biologic medicines and biosimilars to healthcare systems, hospitals, and patients, making money from branded drug sales, long-duration franchises, and follow-on biologic products. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Innovative biologic drugs | [Data unavailable] | → | Core earnings engine, likely supported by mature blockbuster portfolio | | Biosimilars | [Data unavailable] | ↑ | Interesting growth lever that can offset some pressure from aging legacy products | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 73.3% | Top tier | Very high margin profile, showing strong pricing power and favorable biologics economics | | Net Margin | 20.98% | Above Average | Still highly profitable even after R&D and operating costs | | ROE | 96.65% | Excellent>20% | Eye-catching, but inflated by heavy leverage and low equity base, so don’t read it as pure business quality alone | --- #### 📈 How's the Growth? **Growth Assessment:** Steady Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > What’s interesting is that Amgen’s **3-year revenue growth of 11.77%** is meaningfully better than its **5-year growth of 7.65%**, which suggests growth has improved rather than faded. But EPS growth has lagged revenue growth over both 3 and 5 years, which usually means some mix of cost pressure, integration costs, financing burden, or portfolio shifts is limiting how much top-line growth drops to the bottom line. --- #### 💰 Financial Health Check **One Sentence:** Think of Amgen like a high-income household with a very reliable paycheck, but also a pretty big mortgage—it can handle the bills, just not as effortlessly as the income alone might suggest. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 630.68% debt-to-equity | <60% safe | 🚨Dangerous | | Current Ratio | 1.14 | >1.5 healthy | ⚠️Tight | | Cash Flow | $20.77/share | >0 | ✅Positive | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $261.43 - 52-Week High: $391.29 - Current: $347.8, **very close to the high half of the range** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | | ●(66.5% position) | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE 24.39x | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PE 24.39x | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, the market seems to be betting on three things: first, Amgen can keep protecting earnings despite a mature product base; second, newer pipeline and biosimilar assets can support moderate growth; and third, the company’s dependable cash generation and dividend make it worth paying more than a typical slow-growth pharma name. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-03-16 | Multiple Yahoo articles highlighted renewed investor attention and valuation debate around Amgen | Neutral — sentiment is active, but this looks more like market discussion than a business-changing event | | 2026-03-03 | Collaboration-linked anti-OX40 clinical studies were discontinued | Negative — another reminder that biotech pipelines are uneven, and not every clinical asset will make it | | 2026-02-27 | Phase 3 trial completed for ABP 206 Opdivo biosimilar candidate | Positive — supports the case that biosimilars can be a practical growth and diversification engine | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 73.3% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | 20.98% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | 96.65% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↑ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↑ | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-12-31 | $4.83 | $5.29 | +9.56% Beat 😀 | | 2025-09-30 | $5.11 | $5.64 | +10.28% Beat 😀 | | 2025-06-30 | $5.39 | $6.02 | +11.64% Beat 😀 | | 2025-03-31 | $4.39 | $4.90 | +11.73% Beat 😀 | **Earnings Trend Interpretation:** Four straight solid beats is worth noting. It usually means management is executing well and Wall Street may still be underestimating earnings resilience. That said, when a company builds a reputation for beating, the bar eventually rises—so continued upside gets harder to surprise with. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 21 firms | 50.0% | | Hold | 18 firms | 42.9% | | Sell | 3 firms | 7.1% | **Target Price:** [Data unavailable] **vs Current Price:** [Data unavailable] **Insider Activity:** Net selling in past 3 months via multiple March 2026 Form F transactions > Worth noting: these transactions are coded **“F”**, which usually means shares were sold to cover taxes on vesting equity, not necessarily an executive making a directional bearish call. So I’d treat this as mild noise rather than a major red flag. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Leverage Risk:** Debt-to-equity is very high and liquidity ratios are not especially comfortable → If financing conditions worsen or growth disappoints, balance-sheet flexibility could become a bigger issue 2. **Pipeline Execution Risk:** Clinical programs can fail or get discontinued, as seen in recent anti-OX40 study-related news → If newer assets underdeliver, Amgen may lean too heavily on mature products 3. **Payout Sustainability Risk:** The indicated payout ratio is **118.14%** → If earnings or cash conversion weaken, dividend growth may become harder to sustain at the same pace --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Amgen is a mature, large-cap biotech leader that looks more like a dependable healthcare cash generator than a speculative biotech bet. > > **Key strength:** Its biggest advantage is strong profitability plus a consistent habit of beating earnings expectations, which gives the stock a “quality compounder” feel. > > **Key risk:** The main thing to watch is leverage—Amgen can clearly service its debt today, but the balance sheet leaves less room for error than the company’s stable brand might imply. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis